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Background: Chromium (Cr) is commonly used as a complementary medicine for diabetes mellitus. Several studies
suggest that Cr intakes may improve glucose metabolism and decrease oxidative stress. Therefore, we aimed to
assess the effects of chromium histidinate (CrHis) supplementation using a range of reliable biomarkers of oxidative
damage and histopathological changes in rats with diabetic retinopathy.
Methods: Diabetes was induced with streptozotocin [(STZ), 55 mg/kg] by intraperitoneal injection in male
Long-Evans rats. Three weeks after STZ injection, rats were divided into four groups, namely, untreated normal
controls, normal rats receiving CrHis (110 μg/kg/day); untreated diabetics and diabetics treated with CrHis
(110 μg/kg/day) orally for 12 weeks.
Results: In the untreated diabetic group, levels of serum glucose, glycosylated haemoglobin (HbA1c), total
cholesterol (TC) and retina malondialdehyde (MDA) were significantly increased, while expressions of retina insulin,
and glucose transporter 1 (GLUT 1) and glucose transporter 3 (GLUT3) and level of serum insulin were decreased.
CrHis supplementation was found to reduce the levels of glucose, HbA1c, total cholesterol and MDA and to
improve the GLUT1, GLUT3 and insulin expressions in STZ-induced diabetic rats. CrHis prevents the changes in the
expressions of GLUT1, GLUT3 and insulin and the level of MDA in the retina tissue, confirming the protective
effect of CrHis supplementation against the retinopathy caused by STZ. Histopathologic findings suggest that the
CrHis-treated diabetic group had normal retinal tissue appearance compared with the untreated diabetic group.
Conclusions: These results verify that CrHis has critical beneficial effects against retinal complications. Although
detailed studies are required for the evaluation of the exact mechanism of the ameliorative effects of CrHis against
diabetic complications, these preliminary experimental findings demonstrate that CrHis exhibits antidiabetic effects
in a rat model of diabetic retinopathy by regulating the glucose metabolism and suppressing retinal tissue damage.
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Diabetic retinopathy is the most common diabetic eye
disease and a leading cause of blindness in working-age
population. The pathophysiology of diabetic retinopathy
is complex and multifactorial. The pathogenic process
involves intricate interactions between oxidative stress
and hyperglycemia [1,2]. Oxidative stress, increasing in
diabetic retina during hyperglycemia, is linked to the
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unless otherwise stated.which is the hallmark of microangiopathy seen in
diabetic retinal disease. In addition, the retina is the neu-
rosensorial tissue of the eye and is extremely rich in
polyunsaturated lipid membranes. This feature makes it
especially sensitive to reactive oxygen species and lipid
peroxidation. Diabetes mellitus increases oxidative stress
and induces vascular leakage and increased retinal vascu-
lar permeability, perhaps causing macular edema which
correlates with vision loss in diabetic retinopathy patients
[3-5]. A strong association between hyperglycemia-
induced retinal oxidative stress and the development of
retinal histopathology has been supported by studies inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tain trace elements supplementation can inhibit diabetes-
induced retinal abnormalities associated with increased
oxidative stress and can be directly and/or indirectly regu-
lated by their interrelated homeostatic mechanisms to en-
sure normal retinal function [6].
In a high energy-demanding tissue such as retina, the
regulation of glucose uptake and its utilization is import-
ant for the maintenance of normal retinal function. It is
well known that glucose uptake is regulated by glucose
transporter proteins (GLUTs) and all mammalian cells
contain one or more members of this GLUT protein fa-
mily. Among these transporters the GLUT3 and GLUT1
isoforms have been expressed in retinal cells [7,8]. Glucose
uptake into retina cells occurs across the blood-retinal
barrier via the GLUT1 and GLUT3 transporters. Glucose
uptake into cells can vary among cell types, and such dif-
ferences might be important in determining which cells
are adversely affected by hyperglycemia [7].
The incidence of diabetes mellitus is associated with
various events such as obesity, increasing age, physical
inactivity etc. Furthermore, certain nutritional deficien-
cies have also been associated with a higher incidence of
diabetes mellitus [8,9]. Chromium (Cr) deficiency has
been associated with elevated blood glucose levels and
diabetes mellitus [9]. Chromium is required for optimal
insulin activity and normal carbohydrate and lipid me-
tabolism [9,10]. Moreover, Cr improves glucose uti-
lization through cellular signal transduction and glucose
transporters. Results from the trials show that Cr sup-
plementation in patients [10] and animals with type 1
and type 2 diabetes can improve both glucose and insu-
lin metabolism [11]; in contrast to some studies rejecting
the importance of Cr in treatment of type 2 diabetes
[12]. For example, Kleefstra et al. [12] reported that no
significant differences were found over time between the
control and Cr treatment in the form of chromium yeast
groups for fasting plasma glucose levels, blood pressure,
body fat percentage, weight, lipid profile, and insulin re-
sistance. However, as a novel Cr chelate, chromium his-
tidinate (CrHis) is absorbed better than other forms of
Cr compounds tested in human subjects [13]. Anderson
et al. [13] reported that that humans absorbed an aver-
age 3.1 mcg of Cr from the CrHis complex, compared to
1.8 mcg from chromium picolinate (CrPic), 0.4 mcg
from chromium chloride and 0.2 mcg from chromium
polynicotinate. However, the exact mechanism by which
supplemental CrHis exerts hypoglycemic action in dia-
betic diabetic retinopathy has not been fully elucidated.
Therefore, this study was specifically planned to evaluate
the effect of CrHis, a form of Cr developed to enhance
stability and absorption of Cr supplementation, on meta-
bolic risk factors and to determine the effect on the ret-
inal tissue damage status of diabetic retinopathy rats.Methods
Animals
Twenty eight Long Evans rats, useful animal model for
studying ocular diabetic complications, aged 8 weeks
with 250 ± 20 g of body weight were obtained from Ertu-
grul Kilic (Yeditepe University, Turkey). All the animals
were kept and maintained under the standard guidelines
and housed in the Veterinary Control Institute (Elazig,
Turkey). The animals were kept and maintained at 22 ± 2°C,
humidity of 55% ± 5% and 12/12-hour light/dark cycle.
The rats were allowed free access to feed [standard pellet
diet] and drinking water. The experiment was approved
by the Animal Care and Use Committee, University of
Firat with ethics number: 2011-10-131. All procedures
involving rats were conducted in strict compliance with
relevant laws, the Animal Welfare Act, Public Health
Services Policy, and guidelines established by the Institu-
tional Animal Care and Use Committee of the University.
The rats were weighed every week and at the end of the
study. Blood sample was collected from the tail vein of
each rat for the measurement of biochemical efficacy and
safety markers.
Materials
The CrHis (Nutrition 21, Purchase, NY) was given in the
water and administered at a concentration of 110 μg/kg
bw/d) to get 9.16 μg elemental Cr (kg body/d), which is an
equivalent dose of 614 μg Cr for a 70-kg adult human
based on a previous work [9]. The Cr concentration of the
water provided the control group was negligible (<1 μg/L).
The water provided the Cr-supplemented group was ini-
tially prepared as a solution containing 3000 μg CrHis/L
of water. The CrPic-supplemented water was diluted to
achieve the target Cr intake per group on the basis of
measured water intake [14]. STZ was obtained from
Sigma (St. Louis, MO). To induce experimental diabetes,
STZ was dissolved in citrate buffer (pH 4.5) and injected
once intraperitoneally at a dose of 55 mg/kg to the re-
mainder of the animals. A control group was given citrate
buffer via intraperitoneal injection.
Experimental design and induction of diabetes
Fourteen rats were treated with STZ (55 mg/kg body
weight) through intraperitoneal injection. All rats were
then fasted for 16 hour prior to treatment, but they had
access to drinking water. The animals were divided into
4 groups: group I (Control) rats received citrate buffer
intraperitoneally and isotonic saline, orally; group II
(Control + CrHis) rats were administered chromium his-
tidinate orally (110 μg/kg body weight) daily for a period
of four weeks; group III (Diabetic) rats received single
injection of STZ (55 mg/kg body weight) intraperitone-
ally and were also given isotonic saline, orally for the
duration of the study; group IV (Diabetic + CrHis)
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chromium histidinate (110 μg /kg body weight) daily for
a period of 12 weeks after the induction of diabetes.
Body weight and blood glucose concentrations were
monitored weekly. Blood was collected from the tail vein
of the rats. Blood glucose was determined by one touch
glucometer (ACCU-Check Active, Roche Diagnostics,
Mannheim, Germany) after the injection for 72 h. Before
STZ injection, glucose concentrations of study rats and
controls were measured and compared. After the injec-
tion of STZ, animals that exhibited fasting glucose levels
greater than 140 mg/dL were considered as neonatal
STZ diabetic resembling diabetes mellitus in humans.
Laboratory analyses
At the end of the experiment, blood samples were
centrifuged at 3000 × g for 10 min and sera were se-
parated. Serum glucose concentrations were measured
by using ACCU-Chek Active (Roche Diagnostics, Basel,
Switzerland). Serum insulin levels were measured with
the Rat Insulin Kit (Linco Research, St Charles, MO) by
enzyme-linked immunosorbent assay (ELISA, Elx-800,
BioTek Instruments, Winooski, VT). Serum concen-
trations of total cholesterol (TC) were measured by diag-
nostic kits (Sigma Diagnostics, St Louis, MO). Blood
glycosylated haemoglobin (HbA1c) was also measured
by routine kit (Alfabiotech, Milano, Italy) using the auto-
analyzer. After rats were sacrificed, both eyes were enu-
cleated and frozen at −80°C for the measurements of
MDA, GLUT1, GLUT3 and insulin. The retina MDA
content was measured by high performance liquid chro-
matography (HPLC, Shimadzu, Tokyo, Japan) using a
Shimadzu UV–vis SPD-10 AVP detector and a CTO-10
AS VP column in a mobile phase consisting of 30 mM
KH2PO4 and methanol (82.5 + 17.5, v/v; pH 3.6) at a
flow rate of 1.2 ml/min. Column effluents were moni-
tored at 250 nm and the volume was 20 μl. The retina
homogenate (10%, w/v) was prepared in 10 mM phos-
phate buffer (pH 7.4), centrifuged at 13,000 × g for
10 min at 4°C, and the supernatant was collected and
stored at −80°C for MDA analysis [15]. For Western blot
analyses protein extraction was performed by homo-
genizing the retina in 1 ml ice-cold hypotonic buffer A,
containing 10 mM 2-[4-(2-Hydroxyethyl)-1-piperazinyl]
ethanesulfonic acid [HEPES] (pH 7.8), 10 mM KCl,
2 mM MgCl2, 1 mM DTT, 0.1 mM EDTA, and 0.1 mM
phenylmethylsulfonyl-fluoride (PMSF). The homogenates
were added with 80 μl of 10% Nonidet P-40 (NP-40) solu-
tion and then centrifuged at 14,000 × g for 2 min. The pre-
cipitates were washed once with 500 μl of buffer A plus
40 μl of 10% NP-40, centrifuged, re-suspended in 200 μl
of buffer C [50 mM HEPES [pH 7.8], 50 mM KCl,
300 mM NaCl, 0.1 mM EDTA, 1 mM dihiothreitol
[DTT], 0.1 mM PMSF, 20% glycerol], and recentrifugedat14,800 × g for 5 min. The supernatants were collected for
determinations of GLUT-1, GLUT-3 and insulin accor-
ding to the method described by Sahin et al. [16]. Equal
amounts of protein (50 μg) were electrophoresed and
subsequently transferred onto a nitrocellulosemembrane
(Schleicher and Schuell Inc., Keene, NH, USA). Anti-
bodies against GLUT-1, GLUT-3 and insulin (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) were diluted
(1:1000) in the same buffer containing 0.05% Tween-20.
Protein loading was controlled sing a monoclonal mouse
antibody against β-actin (A5316; Sigma). Bands were ana-
lyzed densitometrically using an image analysis system
(Image J; National Institute of Health, Bethesda, USA).
Histopathology
After the eye extirpation, tissue (retina) of each rat was
examined grossly. The tissue was removed for histologic
study, washed with normal saline, and immersion-fixed
in 10% buffered formalin immediately upon removal.
They were gradually dehydrated, embedded in paraffin,
cut into 5-μm sections, and stained with hematoxylin
and eosin for histologic examination according to stan-
dard procedures.
Statistical analysis
Data were analyzed statistically using one-way ANOVA.
In the analyses for serum glucose HbA1c, total choles-
terol, and insulin concentrations, the repeated statement
was added in the general linear model. The group diffe-
rences were attained by the Fisher's multiple comparison
test [Statistical Package for the Social Sciences (SPSS),
Version 17.0, Chicago, IL]. A P value of less than 0.05
was considered significant.
Results
Effect of CrHis upon body weight and blood analysis in
the rats diabetic-induced by streptozotocin
STZ administration affected the levels of typical blood
parameters characteristic for diabetes, which are also
accepted values in diabetes diagnostic (glucose, insulin
and HbA1c). Blood glucose, HbA1c and total cholesterol
levels were significantly increased in untreated diabetic
rats compared to control groups while insulin levels
were decreased (P < 0.5). When diabetic retinopathy rats
were treated with CrHis, significant increases in blood
glucose, HbA1c, insulin and total cholesterol levels were
observed in diabetic retinopathy rats. CrHis treatment
also resulted in a significant decrease in mean serum
total cholesterol concentration of diabetic retinopathy ani-
mals. Body weight was significantly decreased (P < 0.001)
in the untreated diabetic rats when compared to con-
trol group. CrHis treatment significantly increased body
weight (P < 0.001) compared to the untreated diabetic
group (Table 1).
Table 1 Effect of CrHis supplementation on biochemical parameters in diabetic rats
Parameters Control CrHis STZ STZ + CrHis
Body weight (g) 330 (3.6)bc 340 (3.9)b 225 (3.5)c 250 (3.5)a
Glucose (mg/dL) 110 (2.3)a 100 (2.0)a 480 (8.0)b 290 (2.7)c
Insulin (μU/mL) 47.4 (0.20)a 50.3 (0.22)a 20.2 (0.25)b 25.0 (0.25)c
Total cholesterol (mg/dL) 90 (0.64)a 80 (0.34)a 240 (0.90)b 218 (0.80)c
Glycosylated hemoglobin (mg/g) 0.29 (0.02)a 0.20 (0.01)a 0.82 (0.05)b 0.45 (0.03)c
Data are expressed as mean (SD). Superscripts denote significant differences (P < .05) between groups.
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expression in the rats diabetic-induced by streptozotocin
Expressions of GLUT1, GLUT3 and insulin showed sig-
nificant upward regulation (P < 0.05) in the retina of dia-
betic rats compared to control. Treatment using CrHis
significantly (P < 0.05) reversed these changes to near
control levels (Figure 1, Panel A-C).
Effect of CrHis upon retinal MDA expression in the rats
diabetic-induced by streptozotocin
The retina of untreated diabetic rats had consider-
ably higher MDA expressions compared with con-
trols (P < 0.001). A statistically significant reduction of
MDA expression was found in retina of diabetic rats
when the diabetic rats were treated with CrHis (Figure 1,
Panel D).
Histopthaology
Retinas were highly organized in the normal (control)
rats, with intact layers. The retinas were disorganized in
the diabetic rats with impaired layers. But the retinas in
CrHis group were improved compared to the diabetes
group (Figure 2).
Discussion
Diabetic retinopathy is the most common microvascular
complication of diabetes. It remains a major cause of
vision impairment or blindness in the world and high
blood sugar level is considered the chief instigator in its
development. The pathogenetic mechanisms of diabetic
retinopathy are rather obscure. Many hyperglycemia-
induced metabolic abnormalities are implicated in its
pathogenesis, such as increased oxidative stress, and in-
creased advanced glycation endproduct formation and
other tissue proteins, which are observed during long-
term hyperglycemia [6]. The retina has a high concen-
tration of polyunsaturated fatty acids and the highest
uptake of oxygen, which are vulnerable to lipid peroxida-
tive damage. Free radical oxidation of the retinal pho-
toreceptors adversely affects visual processing after the
loss of lipoprotein membrane content [3,4]. Animal
studies have demonstrated that oxidative stress, increa-
sing in retina during hyperglycemia, is linked to the
retinal capillary basement membrane thickening, whichis one of the earliest abnormalities of the microangiopa-
thy seen in diabetic retinopathy [4,5]. Hyperglycemia is
generally recognized as a primary cause of diabetic com-
plications and is associated with increased serum level of
MDA [3,17]. In regards to diabetes mellitus, MDA levels
are increased, indicating increasing lipid peroxidation.
Diabetes induced oxidative stress can be responsible for
the development of diabetic complications [17]. Trace
elements and oxidative stress are associated with gly-
cemic control and diabetic complications and trace ele-
ments supplementations such as Cr may help diabetic
patients to slow the progression of this threatening com-
plication of diabetes [9-11]. These findings were sup-
ported by a significant increase in MDA levels in retina
tissue of diabetic retinopathy rats compared to other
groups in our study. However, levels of MDA were sig-
nificantly lower in the CrHis administration group and
these research results were consistent with those ob-
tained in other studies and in agreement that supple-
mentation to diet of some essential trace metals such as
Cr may play a role in the improvement of diabetes melli-
tus complications.
The risk of loss in visual acuity was correlated with the
degree of retinal hard exudates, reducing serum lipid levels
in patients with diabetic retinopathy [18]. The most com-
mon lipoprotein pattern in diabetes, also known as diabetic
dyslipidemia, consists of an increase in triglyceride levels
and decrease in high-density lipoprotein (HDL) cholesterol
levels [19]. This is consistent with the study carried out by
Yan et al. [20] to elucidate the relationship between dia-
betes and increase in serum cholesterol level. Faulkner
et al. [21] clearly showed that the control of impaired gly-
caemic, which is defined by HbA1c, was proportionally re-
lated with degree of dyslipidemia. In addition, Cefalu [22]
found that Cr supplementation improved glycemic control
of type 2 diabetics by decreasing HbA1c% concentration.
Jain et al. [23] also recorded that Cr is a key mineral for
protection from heart diseases in streptozotocin-treated
diabetic rats by reducing cholesterol levels in blood. In par-
allel with previous research, our study demonstrated that
CrHis supplementation lowered total cholesterol level, and
improved the HbA1c level in diabetic rats.
As one of the essential trace elements, trivalent cr
plays a significant role in the regulation of glucose and
Figure 1 Effect of chromium supplementation on the expression, GLUT1 (Panel A), GLUT3 (Panel B), insulin (Panel C), MDA (Panel D)
values and density of proteins (Panel E) in the retina tissue regions of DR rats. Data are means of quadruplets of assays and expressed as
relative to control (%). Blots were repeated at least 3 times (n = 3) and a representative blot for each is shown. Actin was included to ensure
equal protein loading. Values are LS means ± SE. Different letters within the retina parts indicate statistical differences among groups (p < 0.05).
Figure 2 Paraffin section photograph(s) of rat retina control and experimental group, control (A), CrHis (B), STZ + CrHis (C) and STZ (D)
showing the histopathological changes.
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part of an oligopeptide–chromodulin (low-molecular-
weight chromium binding substance)–potentiating the
effect of insulin by facilitating insulin binding to recep-
tors at the cell surface. With Cr acting as a cofactor of
insulin, Cr activity in the organism is parallel to insulin
functions [24]. Cefalu et al. [25] stated that Chinese pa-
tients with type 2 diabetes receiving Cr experienced sig-
nificant improvements in HbA1c, fasting serum glucose,
2-h glucose, and fasting and 2-h insulin. Similarly, Sahin
et al. [9] reported that supplementary CrPic reduced
blood glucose, total cholesterol levels and free fatty acid
concentration and increased serum insulin levels and the
composite insulin sensitivity index in rats. These results
were also in agreement with Anderson et al. [26]. In
addition Chen et al. [27] indicated that Cr supplementa-
tion has significant positive effects on glucose and insu-
lin metabolism in patients with diabetes. This agreed
with results of several authors such as Ravina et al. [28]
who demonstrated that 10 days of treatment with CrPic
(200 μg/Cr day) significantly increased insulin sensitivity
in patients with type 1 or 2 diabetes and also enabled re-
ductions in dosages of insulin and/or oral antidiabetic
drugs in these patients. In the present study, the benefi-
cial effect of Cr supplementation in diabetic retinopathy
rats was observed in improvements in blood glucose and
HbA1c levels. Complications of diabetic retinopathy
were also shown to slow significantly while the same
trend was observed for the carbohydrate metabolic pro-
file as reflected in improved values of insulin expression
and glucose transporter proteins.
Chromium has consistently indicated improvement in
glucose transport in various tissues both in vitro and in
animal models. Several mechanistic studies have demon-
strated improvements in insulin receptor/postreceptor
signaling, leading to enhanced activity of GLUTs. Inter-
estingly, Cr can directly bind insulin, making the insulin
more stable and possibly prolong its duration of action.
Chromium treatment also helps the translocation of
GLUTs and increases membrane fluidity by reducing the
plasma membrane cholesterol [29]. The retina tissue has
a high concentration of polyunsaturated fatty acids and
high metabolic rates that require a constant and abun-
dant supply of glucose from the circulation to meet their
metabolic demands. Therefore, glucose uptake by this
tissue plays an important role in determining glycemic
control. In the retina, glucose is transported by GLUT1
[30] and GLUT3 [31] across the blood–retinal barrier.
GLUT1 levels in the retina increase in relation to
glucose transport and metabolism and tissue growth,
whereas GLUT3 levels in neuroretina increase in rela-
tion to functional neuronal activity [32]. In the retina,
endothelial cells express GLUT-1 [33], whereas neurons
express GLUT3 [32]. Some studies have demonstratedthat hyperglycemia plays a critical role in the patho-
genesis of retinal disease. Klip et al. [34] indicated that
whole-body glucose uptake is decreased in streptozocin-
induced diabetic animals and in type 2 diabetic humans.
In the diabetic retinopathy model, the observed lower
expressions of GLUT1 and GLUT3 in the retina indicate
the cellular biological properties similar to those of a
combination of neurons and endothelial cells. Moreover,
CrHis treatment effectively reversed this decrease in the
retina. Increased GLUT1 and GLUT3 expressions in ret-
ina tissues upon hyperglycemia may be a response to
compensate glucose need (Figure 1). Chromium serves
as a cofactor for insulin action and enhances insulin sig-
naling in animal models [35]. As examples, Cr supple-
mentation has alleviated insulin resistance, enhanced
intracellular insulin signaling in high fat diet/STZ rats,
depressed lipolysis in adipocytes and inhibited gluconeo-
genesis in rats. Another study also reported an inverse
association of Cr intake with fasting insulin level and
several studies have reported benefits of chromium sup-
plementation on insulin sensitivity in adults with or
without type 2 diabetes mellitus [9]. Chromium supple-
mentation can alleviate blurred vision and improve poor
insulin binding and impaired glucose intolerance in
human and animals [36]. These observations suggest
that CrPic supplementation improves insulin sensitivity
and improves retinal function by recovering retinal chro-
mium concentration. Chromium can modulate the ac-
tivity of insulin by increasing the insulin-sensitive cell
receptors or binding activity and enhancing intracellular
insulin signaling activity [37]. Insulin stimulates cellular
glucose uptake in various tissues by inducing the trans-
location of GLUT from an intracellular pool to the
plasma membrane [38]. The hypoglycemic effect of tri-
valent chromium was reported under insulin-deficient
conditions [39] and exhibited significant antidiabetic po-
tential in STZ-induced diabetes in rats. Our findings
demonstrate that diabetic retinopathy syndrome in rats
is associated with a reduction in retina tissue insulin
levels, which reflects impairment in glucose uptake. This
is further supported by other blot test examinations of
retina tissues. Treatment of diabetic retinopathy rats
with CrHis succeeded to normalize the lower retina in-
sulin level. This may explain the reported effectiveness
of CrHis treatment on the retina tissue levels of insulin.
Conclusions
In conclusion, the results of the present study demon-
strate the benefits of supplementation with CrHis in rats
with diabetic retinopathy. CrHis supplementation offer
improvements to markers of disease risk, including hyper-
glycemia insulin sensitivity, and increased oxidative stress.
These findings are encouraging and warrant further clin-
ical trials of this promising CrHis supplementation.
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